-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $124

Benzinga·01/16/2026 15:19:48
Listen to the news
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $115 to $124.